Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 109

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 109
---
 of such shares in the public market could adversely affect the market price of
our Common Stock.

In addition to this prospectus,
we have filed (in each case, the share number set forth below has been adjusted for the Reverse Stock Split):

| ● | a registration                                                                                                                    
 statement with the SEC for purposes of registering the resale from time to time of up to 2,100,000 Shares of Common Stock, which  
 consists of (i) 2,086,357 shares of Common Stock under the New Keystone Purchase Agreement and (ii) 13,643 shares of Common Stock 
 under the Old Keystone Purchase Agreement;                                                                                        |

| ● | a registration statement                                                                                                         
 with the SEC for purposes of registering the resale from time to time of up to 266,191 Shares of Common Stock, which consists of 
 (i) 250,000 Keystone Purchase Shares, (ii) 6,191 Keystone Commitment Shares, and (iii) 10,000 Arena Commitment Shares;           |

| ● | a registration statement                                                                                                                   
 with the SEC for purposes of registering (1) the resale from time to time of up to 357,737 shares of Common Stock, which consists          
 of (i) 20,557 shares of Common Stock issued to certain selling securityholders for their portion of the merger consideration in connection 
 with the consummation of the Business Combination in exchange for shares of common stock of Legacy CERo; (ii) 200,800 shares of Common     
 Stock issuable upon the conversion of shares of our Series A Preferred Stock, purchased by certain investors pursuant to the First         
 Securities Purchase Agreement; (iii) 12,520 shares of Common Stock issuable upon the conversion of shares of our Series B Preferred        
 Stock, purchased by certain investors pursuant to the Second Securities Purchase Agreement; (iv) 31,712 shares of Common Stock initially   
 issued to the Sponsor and distributed to its members in a distribution-in-kind immediately prior to the Business Combination; (v)          
 10,000 shares of Common Stock issued to the Sponsor, which are subject to forfeiture upon the vesting of the Tertiary Earnout Shares;      
 (vi) 1,850 shares of Common Stock issued to investors other than the Sponsor in a private placement concurrently with the Initial          
 Public Offering; (vii) 16,495 shares of our Common Stock issued to certain third-party vendors and service providers; (viii) 3,250         
 shares of Common Stock issuable upon the